Clinical inhibition of CYP2D6‐catalysed metabolism by the antianginal agent perhexiline

Aims Perhexiline is an antianginal agent that displays both saturable and polymorphic metabolism via CYP2D6. The aim of this study was to determine whether perhexiline produces clinically significant inhibition of CYP2D6‐catalysed metabolism in angina patients. Methods The effects of perhexiline on...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2004-04, Vol.57 (4), p.456-463
Hauptverfasser:	Davies, Benjamin J. L., Coller, Janet K., James, Heather M., Gillis, David, Somogyi, Andrew A., Horowitz, John D., Morris, Raymond G., Sallustio, Benedetta C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angina Pectoris - drug therapy Antianginal agents. Coronary vasodilator agents Biological and medical sciences Cardiovascular Agents - therapeutic use Cardiovascular system CYP2D6 Cytochrome P-450 CYP2D6 Inhibitors dextromethorphan Dextromethorphan - urine Dextrorphan - urine Drug Interactions Female genotype Humans Male Medical sciences metabolic ratio perhexiline Perhexiline - therapeutic use Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!